The International Federation of Gynecology and Obstetrics (FIGO) staging systems for vulva, cervix, endometrium, and sarcomas have been revised for the first time in over a decade. The purpose of ...

Recurrent or Persistent Carcinoma of the Cervix Endometrial GOG 122 (2007) A Randomized Trial of Whole Abdominal Irradiation and Combination Chemotherapy in Advanced Endometrial Carcinoma LAP-2 ...

The first opinion recommends the approval of Keytruda in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the first-line treatment of adult patients with ...

Recent research has revealed unexpected health benefits linked to coffee, despite earlier recommendations to limit intake due ...

From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held in Xiamen.

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

Cervical SCC, spreading superficially to the inner surface of the uterus and replacing the endometrium with carcinoma cells, is called superficial spreading SCC (2). It is not included in the 2020 ...

“Patients with recurrent ovarian and endometrial cancers are already ... histologies (uterine carcinosarcoma and uterine serous carcinoma) and p53 mutant genotypes, well known for adverse ...

Meanwhile, Keytruda has an FDA green light in advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or dMMR in March 2022, as well as in a combination regimen alongside ...

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

Oct. 1 marked a remission milestone for Bonnie Schmitz, the Gift Shoppe coordinator at Jamestown Regional Medical Center. "I've never had five years since 2010," she said. "It's a big, big celebration ...

The latest authorisation comes just three months after the company received expanded approval from the FDA for a Keytruda/carboplatin and paclitaxel regimen in primary advanced or recurrent ...